>It could the very thing that was making finances difficult for several reasons.
Could anyone expand on this thesis? Why would the Hunt's getting 10% of future revenues be a dealblocker for financing? I can see why if the percentage was larger, but 10%?
There is speculation/assumption here that this buy-back of the 10% is somehow related to financing. I am not convinced - no one here knows, so this is guessing, not fact.
I think the fundamental issue for financing will be to convince the potential investor(s) that the science will make it thru FDA drug testing Phases. That's how the investor(s) will see a return on their investment - drug licensing agreements. Whether 90% or 100% of those big $$ licensing agreements makes it to CYGX seems much less important than whether those revenues will ever EXIST or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.